- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.10. | IMMUNEONCO-B (01541): INSIDE INFORMATION - PROPOSED PARTICIPATION IN THE H SHARE FULL CIRCULATION PROGRAMME BY THE COMPANY | - | HKEx | ||
| 24.10. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF SLE | 1 | HKEx | ||
| 14.10. | IMMUNEONCO-B (01541): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 14.10. | IMMUNEONCO-B (01541): (1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR | 1 | HKEx | ||
| 30.09. | IMMUNEONCO-B (01541): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 30.09. | IMMUNEONCO-B (01541): (1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR | - | HKEx | ||
| 27.09. | IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTION - SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT | - | HKEx | ||
| 23.09. | IMMUNEONCO-B (01541): 2024 INTERIM REPORT | - | HKEx | ||
| 16.09. | Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer | 99 | GlobeNewswire (Europe) | Global registrational strategy in first-line non-squamous and squamous non-small cell lung cancer (NSCLC)Global registrational strategy in first-line triple-negative breast cancer (TNBC)Initiation... ► Artikel lesen | |
| 16.09. | IMMUNEONCO-B (01541): INSIDE INFORMATION - UPDATE ON GLOBAL REGISTRATIONAL STRATEGY FOR IMM2510 FOR NON-SMALL CELL LUNG CANCER AND TRIPLE-NEGATIVE BREAST ... | 1 | HKEx | ||
| 13.09. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - TRANSFER OF EQUITY INTEREST IN A SUBSIDIARY | - | HKEx | ||
| 11.09. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FURTHER PAYMENT RECEIVED UNDER THE LICENSE AND COLLABORATION AGREEMENT WITH SYNBIOTX FOR IMM2510 AND IMM27M | 1 | HKEx | ||
| 10.09. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE MOVEMENTS | 2 | HKEx | ||
| 04.09. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 04.09. | IMMUNEONCO-B (01541): INSIDE INFORMATION - COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY | 1 | HKEx | ||
| 03.09. | IMMUNEONCO-B (01541): INSIDE INFORMATION - THE H SHARE FULL CIRCULATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE | 1 | HKEx | ||
| 26.08. | IMMUNEONCO-B (01541): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024 | - | HKEx | ||
| 22.08. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPFRONT PAYMENT RECEIVED UNDER THE LICENSE AND COLLABORATION AGREEMENT WITH SYNBIOTX FOR IMM2510 AND IMM27M | - | HKEx | ||
| 14.08. | IMMUNEONCO-B (01541): DATE OF BOARD MEETING | - | HKEx | ||
| 14.08. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 14.08.2024 | 424 | Xetra Newsboard | The following instruments on XETRA do have their first trading 14.08.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.08.2024
Aktien
1 CNE100006624 Immuneonco Biopharmaceuticals... ► Artikel lesen |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,235 | +2,83 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Meningitis/ Enzephalitis-Panel zur Unterstützung der Notfalldiagnostik | QIAstat-Dx Meningitis/Enzephalitis-Panel in den USA für den klinischen Einsatz zugelassen, um Diagnosen von Infektionen des zentralen Nervensystems zu unterstützen // Vierte FDA-Zulassung in 2024 markiert... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 46,790 | -0,02 % | Tarsus Pharmaceuticals, Inc: Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer | IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize... ► Artikel lesen | |
| EVOTEC | 7,865 | +9,24 % | Evotec Aktie: Erfolgreich auf Kurs! | ||
| ADMA BIOLOGICS | 19,720 | 0,00 % | Should ADMA Biologics Stock Be in Your Portfolio Pre-Q3 Earnings? | ||
| VERA THERAPEUTICS | 49,040 | +2,29 % | Vera Therapeutics reports Q3 results | ||
| AVIDITY BIOSCIENCES | 47,510 | +0,57 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001) | SAN DIEGO, Oct. 3, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 10,400 | +7,66 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| ARCELLX | 99,16 | +6,65 % | Navigating 7 Analyst Ratings For Arcellx | ||
| APOGEE THERAPEUTICS | 58,05 | 0,00 % | Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer | SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,100 | 0,00 % | Why Summit Therapeutics Stock Was a Winner Today | ||
| RECURSION PHARMACEUTICALS | 6,930 | 0,00 % | Recursion Pharmaceuticals EPS of -$0.34 misses by $0.01, revenue of $26.1M misses by $3.73M | ||
| CELULARITY | 3,090 | 0,00 % | Celularity Inc - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 33,090 | +0,27 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors to be Presented at ... | - Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with... ► Artikel lesen | |
| DYNE THERAPEUTICS | 29,270 | 0,00 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| IMMUNOVANT | 29,930 | -4,74 % | Immunovant Inc.: Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 | Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves' disease... ► Artikel lesen |
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,825 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC finden Sie auf Wallstreet Online.
